Opportunity Information: Apply for RFA RM 10 018
Apply for RFA RM 10 018
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Technology Development for New Affinity Reagents Against the Human Proteome (U54)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310 Trans NIH Research Support.
- This funding opportunity was created on Dec 3, 2010 and posted on Dec 3, 2010.
- Applicants must submit their applications by Feb 4, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $5,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- Eligible applicants include: Independent school districts City or township governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities County governments Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal governments (Federally recognized) For profit organizations other than small businesses State governments Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Technology Development for New Affinity Reagents Against the Human Proteome (U54) opportunity, Funding Opportunity Number RFA-RM-10-018, is a National Institutes of Health (NIH) cooperative agreement aimed at strengthening the NIH Common Fund Protein Capture Program. The long-term purpose of the Protein Capture Program is to build a broadly accessible, community-scale resource of high-quality, renewable affinity reagents that can be generated for essentially all human proteins. In practical terms, the NIH is trying to help the research community overcome a major bottleneck in proteomics and biomedical research: the lack of reliable, standardized, and scalable tools (such as antibodies and other binding reagents) that can specifically capture, detect, or measure individual proteins across the entire human proteome.
This FOA focuses specifically on technology development and improvement. It solicits applications proposing approaches that can produce protein affinity reagents at high throughput and low cost, with an emphasis on readiness for true proteome-scale production within a three- to five-year window. A key point is that the NIH is not looking for purely speculative concepts. Proposed technologies are expected to have already demonstrated solid proof of principle, meaning there should be credible early evidence that the approach works. The gap the NIH wants applicants to address is scalability: taking an approach that works in limited tests and developing it into a robust, repeatable, and cost-effective system that could operate at the scale required to cover the full human proteome.
Another defining feature of this announcement is its pipeline orientation. The NIH frames affinity reagent generation as an end-to-end production pipeline that runs from target selection (choosing which proteins, domains, isoforms, or epitopes to pursue) through reagent generation and on to validation (demonstrating specificity, performance, and suitability for intended uses). Applications are expected to describe technology development in that full pipeline context, not as isolated technical tweaks. The proposed work can span the entire process or focus primarily on one or more stages, but the application should explain how improvements at that stage will increase overall throughput, reduce cost, and improve the quality and reliability of the resulting affinity reagents. In other words, even if a project concentrates on, for example, validation methods or antigen production, it still needs to connect that improvement to measurable gains in the complete production workflow.
The award mechanism is a U54 cooperative agreement, which typically indicates substantial NIH involvement and coordination compared with a standard research grant. That aligns with the program goal of building a community resource and developing approaches that can be integrated into larger, coordinated efforts. The program sits within NIH’s trans-NIH research support (CFDA 93.310), reflecting that it is intended to serve multiple institutes and the broader biomedical research enterprise rather than a single disease area.
From an applicant standpoint, the opportunity was posted December 3, 2010, with an original and current closing date of February 4, 2011, and it was archived March 7, 2011. The estimated total funding amount listed is $5,000,000, with an award ceiling of $1,000,000, and there is no cost sharing or matching requirement. Eligibility is broad and includes public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses and other than small businesses), state and local governments, tribal governments and organizations, public housing authorities, and a range of mission-specific institution types such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Tribally Controlled Colleges and Universities. The eligibility list also explicitly includes non-U.S. entities (foreign organizations), regional organizations, U.S. territories or possessions, and eligible federal agencies, indicating NIH openness to a wide range of performers as long as the proposed technology development is compelling and aligned with the program goals.
Overall, this FOA is best understood as an NIH investment in turning promising affinity reagent technologies into scalable, production-ready systems that can reliably generate validated reagents in large numbers. The emphasis is on building the technological backbone needed to support proteome-wide studies by making affinity reagents cheaper, faster to produce, more reproducible, and more rigorously validated, ultimately enabling a durable community resource that many different areas of biomedical research can use. For further details, the announcement points applicants to the full FOA at http://grants.nih.gov/grants/guide/rfa_files/RFA-RM-10-018.html and provides NIH Office of Extramural Research contact routes for access or linking issues.
Frequently Asked Questions (FAQs)
What is the funding opportunity?
The opportunity is titled "Technology Development for New Affinity Reagents Against the Human Proteome (U54)." It is a National Institutes of Health (NIH) cooperative agreement intended to strengthen the NIH Common Fund Protein Capture Program.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-RM-10-018.
What is the main goal of this program?
The long-term goal of the NIH Common Fund Protein Capture Program is to build a broadly accessible, community-scale resource of high-quality, renewable affinity reagents that can be generated for essentially all human proteins.
What problem is NIH trying to solve with this FOA?
This FOA targets a major bottleneck in proteomics and biomedical research: the lack of reliable, standardized, and scalable tools (including antibodies and other binding reagents) that can specifically capture, detect, or measure individual proteins across the entire human proteome.
What types of projects does this FOA emphasize?
The FOA focuses on technology development and improvement, specifically approaches that can produce protein affinity reagents at high throughput and low cost, with an emphasis on being ready for true proteome-scale production within a three- to five-year window.
Is this FOA looking for early-stage, speculative concepts?
No. NIH indicates it is not looking for purely speculative concepts. Proposed technologies are expected to have demonstrated solid proof of principle, meaning there should be credible early evidence that the approach works.
What is the key development gap NIH wants applicants to address?
The gap is scalability: taking an approach that works in limited tests and developing it into a robust, repeatable, and cost-effective system capable of operating at the scale required to cover the full human proteome.
How does NIH describe the affinity reagent effort in this FOA?
NIH frames affinity reagent generation as an end-to-end production pipeline. The pipeline runs from target selection (choosing proteins, domains, isoforms, or epitopes) through reagent generation and then validation (demonstrating specificity, performance, and suitability for intended uses).
Do applications need to address the full pipeline?
Applications are expected to describe technology development in the context of the full pipeline rather than isolated technical tweaks. A proposed project can span the full process or focus on one or more stages, but it should explain how improvements at that stage affect overall throughput, cost, and reagent quality/reliability across the complete workflow.
If a project focuses only on one stage (like validation), is that allowed?
Yes, the work can focus primarily on one or more stages (for example, validation methods or antigen production). However, the application should connect those improvements to measurable gains in the end-to-end production workflow, including throughput, cost reduction, and quality.
What is the award mechanism for this opportunity?
The award mechanism is a U54 cooperative agreement.
What does a U54 cooperative agreement imply in this context?
A U54 cooperative agreement typically indicates substantial NIH involvement and coordination compared with a standard research grant. In this program, that aligns with the goal of building a community resource and developing approaches that can be integrated into larger, coordinated efforts.
What program or broader NIH effort does this FOA support?
This FOA supports the NIH Common Fund Protein Capture Program and is described as trans-NIH research support intended to serve multiple institutes and the broader biomedical research enterprise rather than a single disease area.
What CFDA number is associated with this program?
The CFDA number listed is 93.310.
When was this opportunity posted?
The opportunity was posted on December 3, 2010.
What was the application closing date?
The original and current closing date listed is February 4, 2011.
Is this funding opportunity still active?
No. It was archived on March 7, 2011.
How much total funding is estimated for this FOA?
The estimated total funding amount listed is $5,000,000.
What is the award ceiling?
The award ceiling is $1,000,000.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement listed.
Who is eligible to apply?
Eligibility is broad and includes: public and private institutions of higher education; nonprofits (with or without 501(c)(3) status); for-profit organizations (including small businesses and other than small businesses); state and local governments; tribal governments and organizations; public housing authorities; and multiple mission-specific institution types such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Tribally Controlled Colleges and Universities.
Are non-U.S. entities eligible to apply?
Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations) and also includes regional organizations, U.S. territories or possessions, and eligible federal agencies.
What kinds of outputs or outcomes is NIH ultimately trying to enable?
NIH is investing in making affinity reagent technologies cheaper, faster to produce, more reproducible, and more rigorously validated, so the research community can rely on a durable, widely accessible resource for proteome-wide studies.
Where can applicants find the full FOA text?
The full FOA is referenced at: http://grants.nih.gov/grants/guide/rfa_files/RFA-RM-10-018.html
What if someone has trouble accessing or linking to the FOA?
The announcement notes that NIH Office of Extramural Research contact routes are provided for access or linking issues.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Expeditionary Maneuver Warfare and Combating Terrorism Basic and Applied Research and Advanced Technology Development
Previous opportunity: Production of Affinity Reagents for Human Transcription Factors (U54)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA RM 10 018
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA RM 10 018) also looked into and applied for these:
| Funding Opportunity |
|---|
| Collaborative Office Rounds (COR) Apply for HRSA 11 076 Funding Number: HRSA 11 076 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Affordable Care Act (ACA) Nurse Education, Practice, Quality and Retention (NEPQR) Program Apply for HRSA 11 041 Funding Number: HRSA 11 041 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Nursing Workforce Diversity Apply for HRSA 11 040 Funding Number: HRSA 11 040 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT CCC) (U01) Apply for RFA NS 11 009 Funding Number: RFA NS 11 009 Agency: National Institutes of Health Category: Health Funding Amount: $1,750,000 |
| Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NEXT sites) (U10) Apply for RFA NS 11 008 Funding Number: RFA NS 11 008 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Data Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT DCC) (U01) Apply for RFA NS 11 010 Funding Number: RFA NS 11 010 Agency: National Institutes of Health Category: Health Funding Amount: $1,250,000 |
| Improving the System of Services for CYSHCN Apply for HRSA 11 067 Funding Number: HRSA 11 067 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Emergency Medical Services for Children (EMSC) Data Analysis Resource Center Demonstration Apply for HRSA 11 060 Funding Number: HRSA 11 060 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,210,000 |
| Research Into The Impact Of Economic Fluctuations On Alcohol Consumption, Drinking Patterns, And Prevention And Treatment Of Problem Drinking And Related Problems (R01) Apply for PA 11 061 Funding Number: PA 11 061 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Into The Impact Of Economic Fluctuations On Alcohol Consumption, Drinking Patterns, And Prevention And Treatment Of Problem Drinking And Related Problems (R21) Apply for PA 11 062 Funding Number: PA 11 062 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Neuroimmune Mechanisms Of Alcohol Related Disorders (R01) Apply for PA 11 064 Funding Number: PA 11 064 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neuroimmune Mechanisms Of Alcohol Related Disorders (R21) Apply for PA 11 065 Funding Number: PA 11 065 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIA Program Project Applications (P01) Apply for PAR 11 066 Funding Number: PAR 11 066 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| MCH PipelineTraining Apply for HRSA 11 064 Funding Number: HRSA 11 064 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Pre Solicitation STRENGTHENING HIV PREVENTION IN NAMIBIA Apply for 674 11 0013 Funding Number: 674 11 0013 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $10,000,000 |
| Epidemiologic Research and Surveillance in Epilepsy (U01) Apply for RFA DP 11 003 Funding Number: RFA DP 11 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $450,000 |
| Public Health Research for the Prevention of Complications of Bleeding Disorders Apply for RFA DD 11 009 Funding Number: RFA DD 11 009 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| The Association of Genetic Biomarkers and Hereditary Hemochromatosis (U01) Apply for RFA DD 11 008 Funding Number: RFA DD 11 008 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Postdoctoral Fellowships in Muscular Dystrophy Research (F32) Apply for PA 11 075 Funding Number: PA 11 075 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Informatics Tools for High Throughput Sequence Data Analysis (SBIR) (R43/R44) Apply for RFA HG 10 019 Funding Number: RFA HG 10 019 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA RM 10 018", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.